Jones R J, Roe E A, Gupta J L
Lancet. 1979 Nov 10;2(8150):977-82. doi: 10.1016/s0140-6736(79)92559-5.
A polyvalent pseudomonas vaccine has been tested in controlled clinical trials at two burns units, in Birmingham and New Delhi, in children and adults with burns more than 15% full skin thickness. None of the vaccinated patients in either trial showed blood cultures containing Pseudomonas aeruginosa, and vaccinees showed raised titres of protective antibody and increased phagocytic activity against Ps. aeruginosa. In the New Delhi unit, where death from Ps. aeruginosa infection is common, the mortality in adults was reduced from 40.6% (13/32) in the unvaccinated group to 6.6% (2/30) in the vaccinated group, and in children from 20.8% (5/24) in the unvaccinated group to 4.8% (1/21) in the vaccinated group.
一种多价假单胞菌疫苗已在伯明翰和新德里的两个烧伤治疗中心针对烧伤面积超过全层皮肤厚度15%的儿童和成人进行了对照临床试验。在两项试验中，接种疫苗的患者均未出现血培养中含有铜绿假单胞菌的情况，且接种疫苗者显示出保护性抗体滴度升高以及针对铜绿假单胞菌的吞噬活性增强。在新德里治疗中心，铜绿假单胞菌感染导致的死亡很常见，在成人中，未接种疫苗组的死亡率为40.6%（13/32），接种疫苗组降至6.6%（2/30）；在儿童中，未接种疫苗组的死亡率为20.8%（5/24），接种疫苗组降至4.8%（1/21）。
